奥施康定联合加巴喷丁治疗癌性神经病理性疼痛的临床疗效及对免疫功能的影响

目的:探讨奥施康定联合加巴喷丁治疗癌性神经病理性疼痛的临床疗效及其对免疫功能的影响。方法:选择2015年6月至2016年7月在我院治疗的癌性神经病理性疼痛患者80例,随机分为两组,每组40例。A组患者接受奥施康定抗痛治疗,B组患者在A组基础上联合加巴喷丁治疗。比较两组患者治疗前后VAS疼痛评分以及癌痛缓解的临床疗效,评价两组患者治疗后的生活质量评分和各项免疫指标的变化情况。结果:两组患者治疗后VAS评分均较治疗前显著降低(P0.05),且B组患者的VAS评分明显低于A组(P0.05),B组患者治疗后疼痛总缓解率显著高于A组(P0.05)。两组患者治疗后的食欲、精神状态、睡眠、日常生活以及人际交往等评分均较治疗前显著降低(P0.05),且B组患者降低的程度显著高于A组(P0.05)。两组患者的免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、CD4~+、CD4~+/CD8~+以及循环免疫复合物(CIC)水平均较治疗前显著上升(P0.05),且B组患者以上指标升高的程度显著高于A组(P0.05)。结论:奥施康定联合加巴喷丁缓解神经病理性癌痛临床疗效显著,并可改善患者的免疫功能,提高其生活质量。

Clinical Efficacy of Oxycontin Combined with Gabapentin in the Treatment of Neuropathic Cancer Pain and the Effect on the Immune Function of Patients

ABSTRACT Objective: To explore the effect of oxycontin combined with gabapentin on the clinical cure and immunity for patients with neuropathic cancer pain. Methods: 80 patients with neuropathic cancer pain were enrolled in our hospital from June to 2016 July, of which patients divided into two groups randomly, Group A(n=40) accepted oxycontin treatment, and Group B (n=40) adopted gabapentin based on the patients in Group A. The VAS score and curative effect of the patients were compared between two groups; The quality of life of all patients were evaluated post-treatment, and the change of immunity indexes were compared and analyzed. Results: The VAS score of all patients was decreased significantly compared with pre-treatment (P<0.05), and the score of Group B was lower than those patients in Group A (P<0.05); The total remission rate of Group B was significantly higher than those of Group A (P<0.05); after treat- ment, the score of appetite, emotion, sleep, daily activities, social communications of all patients decreased significantly compared with pre-treatment (P<0.05), and the change of Group B was decrease significantly higher than those patients in Group A (P<0.05); the im- mune index of two groups was significantly increased (P<0.05), and the level of the indexes including IgG, IgA, IgM, CD4⁺, CD4⁺/CD8⁺ and circulating immune complex (CIC) increased compared with pre-treatment remarkably (P<0.05), and which change in Group B was significantly higher than Group A (P<0.05). Conclusion: Oxycontin combined with gabapentin for patients with neuropathic cancer pain deserved popularization in clinical, and which not only possessed well clinical effect, but also increased the quality of life.